Outcome for adolescent and young adult patients with osteosarcoma

A report from the Children's Oncology Group

Katherine A. Janeway, Donald A. Barkauskas, Mark D. Krailo, Paul A. Meyers, Cindy L. Schwartz, David H. Ebb, Nita L. Seibel, Holcombe E. Grier, Richard Gorlick, Neyssa Marina

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

BACKGROUND: There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. METHODS: Patients with high-grade osteosarcoma of any site enrolled on North American cooperative group trials CCG-7943, POG-9754, INT-0133, and AOST0121 were included in this study. Primary tumor site, age, sex, ethnicity, histologic response, and presence of metastatic disease at diagnosis were evaluated for their impact on overall survival (OS) and event-free survival (EFS). RESULTS: A total of 1054 patients were eligible and had complete data available for the study. Age was not significantly associated with any other presenting covariate analyzed except sex. Age 18 or older was associated with a statistically significant poorer EFS (P =.019) and OS (P =.043). The 10-year EFS and OS in patients <10, 10 to 17, and ≥18 years old were 55%, 55%, 37% and 68%, 60%, 41%, respectively. The poorer EFS in patients ≥18 years old was because of an increased rate of relapse. Presence of metastatic disease at diagnosis, poor histologic response, and pelvic tumor site were also associated with a poorer prognosis. In multivariate analysis, age continued to be associated with poorer EFS (P =.019) and OS (P =.049). CONCLUSIONS: In osteosarcoma, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, histologic response, or metastatic disease at presentation. Cancer 2012. © 2012 American Cancer Society. In children and young adults with osteosarcoma enrolled on North American cooperative group trials, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, a higher incidence of poor histologic response, or metastatic disease at presentation.

Original languageEnglish (US)
Pages (from-to)4597-4605
Number of pages9
JournalCancer
Volume118
Issue number18
DOIs
StatePublished - Sep 15 2012

Fingerprint

Osteosarcoma
Young Adult
Disease-Free Survival
Survival
Neoplasms
Recurrence
Multivariate Analysis
Age Groups
Incidence

Keywords

  • adolescent
  • osteosarcoma
  • outcome
  • prognosis
  • young adult

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Janeway, K. A., Barkauskas, D. A., Krailo, M. D., Meyers, P. A., Schwartz, C. L., Ebb, D. H., ... Marina, N. (2012). Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group. Cancer, 118(18), 4597-4605. https://doi.org/10.1002/cncr.27414

Outcome for adolescent and young adult patients with osteosarcoma : A report from the Children's Oncology Group. / Janeway, Katherine A.; Barkauskas, Donald A.; Krailo, Mark D.; Meyers, Paul A.; Schwartz, Cindy L.; Ebb, David H.; Seibel, Nita L.; Grier, Holcombe E.; Gorlick, Richard; Marina, Neyssa.

In: Cancer, Vol. 118, No. 18, 15.09.2012, p. 4597-4605.

Research output: Contribution to journalArticle

Janeway, KA, Barkauskas, DA, Krailo, MD, Meyers, PA, Schwartz, CL, Ebb, DH, Seibel, NL, Grier, HE, Gorlick, R & Marina, N 2012, 'Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group', Cancer, vol. 118, no. 18, pp. 4597-4605. https://doi.org/10.1002/cncr.27414
Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH et al. Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group. Cancer. 2012 Sep 15;118(18):4597-4605. https://doi.org/10.1002/cncr.27414
Janeway, Katherine A. ; Barkauskas, Donald A. ; Krailo, Mark D. ; Meyers, Paul A. ; Schwartz, Cindy L. ; Ebb, David H. ; Seibel, Nita L. ; Grier, Holcombe E. ; Gorlick, Richard ; Marina, Neyssa. / Outcome for adolescent and young adult patients with osteosarcoma : A report from the Children's Oncology Group. In: Cancer. 2012 ; Vol. 118, No. 18. pp. 4597-4605.
@article{5fafe3809d9e40929af3fabebe6a5938,
title = "Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group",
abstract = "BACKGROUND: There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. METHODS: Patients with high-grade osteosarcoma of any site enrolled on North American cooperative group trials CCG-7943, POG-9754, INT-0133, and AOST0121 were included in this study. Primary tumor site, age, sex, ethnicity, histologic response, and presence of metastatic disease at diagnosis were evaluated for their impact on overall survival (OS) and event-free survival (EFS). RESULTS: A total of 1054 patients were eligible and had complete data available for the study. Age was not significantly associated with any other presenting covariate analyzed except sex. Age 18 or older was associated with a statistically significant poorer EFS (P =.019) and OS (P =.043). The 10-year EFS and OS in patients <10, 10 to 17, and ≥18 years old were 55{\%}, 55{\%}, 37{\%} and 68{\%}, 60{\%}, 41{\%}, respectively. The poorer EFS in patients ≥18 years old was because of an increased rate of relapse. Presence of metastatic disease at diagnosis, poor histologic response, and pelvic tumor site were also associated with a poorer prognosis. In multivariate analysis, age continued to be associated with poorer EFS (P =.019) and OS (P =.049). CONCLUSIONS: In osteosarcoma, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, histologic response, or metastatic disease at presentation. Cancer 2012. {\circledC} 2012 American Cancer Society. In children and young adults with osteosarcoma enrolled on North American cooperative group trials, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, a higher incidence of poor histologic response, or metastatic disease at presentation.",
keywords = "adolescent, osteosarcoma, outcome, prognosis, young adult",
author = "Janeway, {Katherine A.} and Barkauskas, {Donald A.} and Krailo, {Mark D.} and Meyers, {Paul A.} and Schwartz, {Cindy L.} and Ebb, {David H.} and Seibel, {Nita L.} and Grier, {Holcombe E.} and Richard Gorlick and Neyssa Marina",
year = "2012",
month = "9",
day = "15",
doi = "10.1002/cncr.27414",
language = "English (US)",
volume = "118",
pages = "4597--4605",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "18",

}

TY - JOUR

T1 - Outcome for adolescent and young adult patients with osteosarcoma

T2 - A report from the Children's Oncology Group

AU - Janeway, Katherine A.

AU - Barkauskas, Donald A.

AU - Krailo, Mark D.

AU - Meyers, Paul A.

AU - Schwartz, Cindy L.

AU - Ebb, David H.

AU - Seibel, Nita L.

AU - Grier, Holcombe E.

AU - Gorlick, Richard

AU - Marina, Neyssa

PY - 2012/9/15

Y1 - 2012/9/15

N2 - BACKGROUND: There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. METHODS: Patients with high-grade osteosarcoma of any site enrolled on North American cooperative group trials CCG-7943, POG-9754, INT-0133, and AOST0121 were included in this study. Primary tumor site, age, sex, ethnicity, histologic response, and presence of metastatic disease at diagnosis were evaluated for their impact on overall survival (OS) and event-free survival (EFS). RESULTS: A total of 1054 patients were eligible and had complete data available for the study. Age was not significantly associated with any other presenting covariate analyzed except sex. Age 18 or older was associated with a statistically significant poorer EFS (P =.019) and OS (P =.043). The 10-year EFS and OS in patients <10, 10 to 17, and ≥18 years old were 55%, 55%, 37% and 68%, 60%, 41%, respectively. The poorer EFS in patients ≥18 years old was because of an increased rate of relapse. Presence of metastatic disease at diagnosis, poor histologic response, and pelvic tumor site were also associated with a poorer prognosis. In multivariate analysis, age continued to be associated with poorer EFS (P =.019) and OS (P =.049). CONCLUSIONS: In osteosarcoma, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, histologic response, or metastatic disease at presentation. Cancer 2012. © 2012 American Cancer Society. In children and young adults with osteosarcoma enrolled on North American cooperative group trials, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, a higher incidence of poor histologic response, or metastatic disease at presentation.

AB - BACKGROUND: There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. METHODS: Patients with high-grade osteosarcoma of any site enrolled on North American cooperative group trials CCG-7943, POG-9754, INT-0133, and AOST0121 were included in this study. Primary tumor site, age, sex, ethnicity, histologic response, and presence of metastatic disease at diagnosis were evaluated for their impact on overall survival (OS) and event-free survival (EFS). RESULTS: A total of 1054 patients were eligible and had complete data available for the study. Age was not significantly associated with any other presenting covariate analyzed except sex. Age 18 or older was associated with a statistically significant poorer EFS (P =.019) and OS (P =.043). The 10-year EFS and OS in patients <10, 10 to 17, and ≥18 years old were 55%, 55%, 37% and 68%, 60%, 41%, respectively. The poorer EFS in patients ≥18 years old was because of an increased rate of relapse. Presence of metastatic disease at diagnosis, poor histologic response, and pelvic tumor site were also associated with a poorer prognosis. In multivariate analysis, age continued to be associated with poorer EFS (P =.019) and OS (P =.049). CONCLUSIONS: In osteosarcoma, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, histologic response, or metastatic disease at presentation. Cancer 2012. © 2012 American Cancer Society. In children and young adults with osteosarcoma enrolled on North American cooperative group trials, age 18 to 30 years is associated with a statistically significant poorer outcome because of an increased rate of relapse. Poorer outcome in adolescent and young adult patients is not explained by tumor location, a higher incidence of poor histologic response, or metastatic disease at presentation.

KW - adolescent

KW - osteosarcoma

KW - outcome

KW - prognosis

KW - young adult

UR - http://www.scopus.com/inward/record.url?scp=84862837194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862837194&partnerID=8YFLogxK

U2 - 10.1002/cncr.27414

DO - 10.1002/cncr.27414

M3 - Article

VL - 118

SP - 4597

EP - 4605

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 18

ER -